title: Impact of Simeprevir Versus Telaprevir Triple Therapy for Chronic Hcv Infection on Patient-Reported Outcomes in Prior Non-Responders to Peginterferon/Ribavirin Results from the Phase Iii Attain Study.
authors.affiliation: Janssen Global Services, LLC, High Wycombe, UK.
authors.forename: J
authors.initials: J
authors.lastname: Scott
authors.affiliation: Janssen Research and Development, Beerse, Belgium.
authors.forename: C
authors.initials: C
authors.lastname: Corbett
authors.affiliation: Janssen Research and Development, Beerse, Belgium.
authors.forename: L
authors.initials: L
authors.lastname: Gilles
authors.affiliation: Janssen Pharmaceutica NV, Beerse, Belgium.
authors.forename: G
authors.initials: G
authors.lastname: Wan
authors.affiliation: Janssen Global Services, Beerse, Belgium.
authors.forename: U
authors.initials: U
authors.lastname: Sbarigia
authors.affiliation: Janssen Pharmaceutica NV, Beerse, Belgium.
authors.forename: W
authors.initials: W
authors.lastname: Jessner